Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 261

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 261
---
 CSL claimed to have obtained a valid German court order in its favor and to endeavor to seek for its enforcement       
 in Israel. Company’s position is that CSL’s claim for the payment of the said unshipped minimum purchase commitments lacks              
 any ground under the terms of the Framework Supply Agreement and moreover, that the Company was never served with German judicial       
 documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the applicable German     
 and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company is in the opinion that      
 the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable German judgement     
 could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s purported ruling.         |

From time to time, the Company has been
and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively, “Legal
Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company believes will
have a material adverse impact on the business or financial statements.

<div align='center'>F-14</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 8:- | SUBSEQUENT EVENTS |

The Company evaluated subsequent events
through January 24, 2025, the date these unaudited interim financial statements were available to be issued. The Company concluded
that no subsequent events have occurred that would require recognition or disclosure in the financial statements, except:

In October 2024, the Company signed an addendum to the 2020 CLA agreement
(the “October 2024 Addendum”) pursuant to which certain lenders (the “Participating Lenders”) under the 2020 CLAs
will increase their CLA and up to an additional aggregate amount of $450. According to the October 2024 Addendum, the 2020 CLAs of the
non-participating Lenders shall bear interest at 8% per annum until maturity commencing as of July 1, 2024, and of the 2020 CLA of the
participating Lenders commencing as of March 31, 2025. In addition, pursuant the October